Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants

I Kister; Tim Spelman; Raed Alroughani; Jeannette Lechner-Scott; P Duquette; F Grand'Maison; Mark Slee; A Lugaresi; M Barnett; P Grammond; Gerardo Iuliano; R Hupperts; M Trojano; H Butzkueven; MSBase Study Group

doi:10.1177/1352458515602640

Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants

I Kister
, Tim Spelman
, Raed Alroughani
, Jeannette Lechner-Scott
, P Duquette
, F Grand'Maison
, Mark Slee
, A Lugaresi
, M Barnett
, P Grammond
, Gerardo Iuliano
, R Hupperts
, M Trojano
, H Butzkueven
, MSBase Study Group

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	17-18
Number of pages	2
Journal	Multiple Sclerosis
Volume	21
Issue number	Supp: 11
DOIs	https://doi.org/10.1177/1352458515602640
Publication status	Published - Sept 2015
Event	31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis - Barcelona, Spain Duration: 7 Oct 2015 → 10 Oct 2015 Conference number: 31

Access to Document

10.1177/1352458515602640Licence: In Copyright

Cite this

Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., Slee, M., Lugaresi, A., Barnett, M., Grammond, P., Iuliano, G., Hupperts, R., Trojano, M., Butzkueven, H., & MSBase Study Group (2015). Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants. Multiple Sclerosis, 21(Supp: 11), 17-18. https://doi.org/10.1177/1352458515602640

@article{f5b6de960529434d9c5740cf68709c82,

title = "Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants",

author = "I Kister and Tim Spelman and Raed Alroughani and Jeannette Lechner-Scott and P Duquette and F Grand'Maison and Mark Slee and A Lugaresi and M Barnett and P Grammond and Gerardo Iuliano and R Hupperts and M Trojano and H Butzkueven and \{MSBase Study Group\}",

year = "2015",

month = sep,

doi = "10.1177/1352458515602640",

language = "English",

volume = "21",

pages = "17--18",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "Supp: 11",

note = "31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS ; Conference date: 07-10-2015 Through 10-10-2015",

}

Kister, I, Spelman, T, Alroughani, R, Lechner-Scott, J, Duquette, P, Grand'Maison, F, Slee, M, Lugaresi, A, Barnett, M, Grammond, P, Iuliano, G, Hupperts, R, Trojano, M, Butzkueven, H & MSBase Study Group 2015, 'Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants', Multiple Sclerosis, vol. 21, no. Supp: 11, pp. 17-18. https://doi.org/10.1177/1352458515602640

Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants. / Kister, I; Spelman, Tim; Alroughani, Raed et al.
In: Multiple Sclerosis, Vol. 21, No. Supp: 11, 09.2015, p. 17-18.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants

AU - Kister, I

AU - Spelman, Tim

AU - Alroughani, Raed

AU - Lechner-Scott, Jeannette

AU - Duquette, P

AU - Grand'Maison, F

AU - Slee, Mark

AU - Lugaresi, A

AU - Barnett, M

AU - Grammond, P

AU - Iuliano, Gerardo

AU - Hupperts, R

AU - Trojano, M

AU - Butzkueven, H

AU - MSBase Study Group

N1 - Conference code: 31

PY - 2015/9

Y1 - 2015/9

UR - http://journals.sagepub.com/doi/pdf/10.1177/1352458515602640

U2 - 10.1177/1352458515602640

DO - 10.1177/1352458515602640

M3 - Meeting Abstract

SN - 1352-4585

VL - 21

SP - 17

EP - 18

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - Supp: 11

T2 - 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Y2 - 7 October 2015 through 10 October 2015

ER -

Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F et al. Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants. Multiple Sclerosis. 2015 Sept;21(Supp: 11):17-18. doi: 10.1177/1352458515602640

Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants

Access to Document

Other files and links

Cite this